National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost-effectiveness of Nilotinib (Tasigna®) for the treatment of chronic phase CML.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 January 2008 February 2008 Reimbursement not recommended.

The cost-effectiveness of nilotinib compared to dasatinib, in patients resistant to imatinib has not been demonstrated.

 Nilotinib (Tasigna) summary